#525USNASDAQ

BIIB

Biogen

$229.41USD

Data as of 2026-10-14

Composite Score54.1Average

Margin of safety+4%Fair value

Fair value$239.94

Target$577.69

Loss chance40%Neutral

SizeLarge cap

SectorHealth Care

DividendNone

TypeCommon stock

Price

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=163)

Quality
Profit margins & asset efficiency
42
Average
Health Care median (n=163) 51
Value
Price vs fundamentals
61
Strong
Health Care median (n=163) 52
Growth
Revenue & earnings trajectory
31
Weak
Health Care median (n=163) 50
Momentum
Recent price strength
82
Exceptional
Health Care median (n=163) 66
Health
Balance sheet & solvency
66
Strong
Health Care median (n=163) 56
Profitability
ROE, ROA, ROIC
49
Average
Health Care median (n=163) 49
Technical
Trend & volatility signals
59
Strong
Health Care median (n=163) 57
Risk
Volatility & drawdown profile
58
Strong
Health Care median (n=163) 47

025405570100

Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Fair price check

3 different valuation methods each estimate what BIIB should be worth, then we compare to today's price.

Near fair value

Models suggest BIIB is priced roughly in line

Today's price

$229.41

Median fair price

$239.94

+5% vs today's price

Of 3 methods:1 say cheap1 say fair1 say pricey

P/B multiplesUndervalued
thinks it's a bargain — estimates $577.69, about 152% above today
P/E multiplesFair
thinks it's fairly priced — estimates $239.94, about 5% above today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $156.71, about 32% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair: $239.94
Margin of safety(vs fair value): +4.4%
Max (ex-outliers): $577.69
Tangible BVPS: —

Stale filing
Value-trap risk (RIM)

Median of all applicable methods (current price $229.41). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$33.87B
Revenue (TTM)	$9.94B
Net income (TTM)	$1.37B
Operating cash flow (TTM)	$2.59B
CapEx (TTM)	$167.90M
Free cash flow (TTM)CFO − CapEx	$2.42B
Total assets	$29.48B
Total liabilities	$10.83B
Stockholders' equity	$14.80B
Cash & equivalents	$2.91B
Shares outstanding	147.64M
EPS (basic)	$9.29
EPS (diluted)	$9.29
P/E ratio (TTM)	24.69

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-04-29
Latest period end: 2026-04-27
Filing lag: 168 days
Missing metrics: 5(gross_profit, operating_income, research_and_development, dividends_paid, ebitda)